Eli Lilly and Company $LLY Stock: Welch & Forbes LLC Lowers Position

Welch & Forbes LLC lessened its position in Eli Lilly and Company (NYSE:LLY) by 0.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 171,447 shares of the company’s stock after selling 1,257 shares during the quarter. Eli Lilly and Company accounts for approximately 2.3% of Welch & Forbes LLC’s portfolio, making the stock its 9th largest holding. Welch & Forbes LLC’s holdings in Eli Lilly and Company were worth $198,378,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LLY. Nemes Rush Group LLC boosted its position in Eli Lilly and Company by 0.6% during the 3rd quarter. Nemes Rush Group LLC now owns 15,668 shares of the company’s stock valued at $18,129,000 after acquiring an additional 93 shares in the last quarter. Pinion Investment Advisors LLC lifted its stake in shares of Eli Lilly and Company by 5.4% in the 3rd quarter. Pinion Investment Advisors LLC now owns 1,454 shares of the company’s stock valued at $1,682,000 after purchasing an additional 75 shares during the period. Montis Financial LLC boosted its holdings in shares of Eli Lilly and Company by 21.2% during the 3rd quarter. Montis Financial LLC now owns 360 shares of the company’s stock valued at $417,000 after buying an additional 63 shares in the last quarter. AEGON ASSET MANAGEMENT UK Plc increased its stake in shares of Eli Lilly and Company by 1.0% during the third quarter. AEGON ASSET MANAGEMENT UK Plc now owns 81,803 shares of the company’s stock valued at $94,653,000 after purchasing an additional 777 shares in the last quarter. Finally, Texas Bank & Trust Co raised its stake in Eli Lilly and Company by 4.1% during the third quarter. Texas Bank & Trust Co now owns 3,497 shares of the company’s stock valued at $4,046,000 after buying an additional 138 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on LLY. Cantor Fitzgerald upped their price objective on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an “overweight” rating in a research report on Monday, November 2nd. Royal Bank Of Canada boosted their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a research report on Friday, October 30th. Argus upped their target price on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a report on Friday, October 30th. Guggenheim increased their price target on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research report on Friday, September 18th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $1,650.00 price objective on shares of Eli Lilly and Company in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,416.64.

Insider Activity

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the sale, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: In a Phase 3 trial, Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity in adults with obesity or overweight. Lilly reported up to an average 44% reduction in breathing interruptions and said it plans to seek U.S. FDA approval for the indication by year-end 2026. An additional use could expand the pill’s commercial opportunity and help it compete with Novo Nordisk’s obesity treatments. Article: Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial
• Positive Sentiment: Jefferies raised its LLY price target to $1,700 from $1,610 and reiterated a Buy rating, signaling continued analyst confidence in the company’s growth outlook. Article: Jefferies raises Eli Lilly price target
• Positive Sentiment: Lilly is expanding digital access to Zepbound and Foundayo through telehealth partnerships with Hims & Hers and LifeMD, potentially broadening the reach of its branded obesity medicines. Article: Eli Lilly opens digital access to obesity drugs
• Negative Sentiment: The FDA issued new warnings about a potential serious eye risk associated with GLP-1 drugs, including Zepbound. The safety alert may raise concerns for patients and prescribers, although the reports provided no Lilly-specific change to the drug’s safety profile. Article: FDA orders new eye-risk warnings for Ozempic and Zepbound

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,413.22 on Tuesday. The firm’s fifty day moving average is $1,220.13 and its 200 day moving average is $1,102.83. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,453.00. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The company has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.87, a PEG ratio of 1.77 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter in the previous year, the business posted $7.02 earnings per share. The business’s revenue was up 38.6% compared to the same quarter last year. Sell-side analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.